UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 11, 2016
Aquinox Pharmaceuticals, Inc.
(Exact name of Registrant as specified in its charter)
| | | | |
| Delaware | | 001-36327 | | 98-0542593 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
450 - 887 Great Northern Way,
Vancouver, B.C.
Canada, V5T 4T5
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (604) 629-9223
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On January 11, 2016, Aquinox Pharmaceuticals, Inc. issued a press release announcing that it had received the official minutes from its December 8, 2015 meeting with the Division of Bone, Reproductive and Urologic Products (DBRUP) of the United States Food and Drug Administration (FDA) and provided an update regarding its development plans for AQX-1125 for the treatment of patients with bladder pain syndrome/interstitial cystitis (BPS/IC). The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| | |
Number | | Description |
| |
| 99.1 | | Press Release of Aquinox Pharmaceuticals, Inc. dated January 11, 2016 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | |
| Aquinox Pharmaceuticals, Inc. |
| |
| By: | | /s/ Kamran Alam |
| Name: | | Kamran Alam |
| Title: | | Chief Financial Officer |
Date: January 11, 2016
INDEX TO EXHIBITS
| | |
Number | | Description |
| |
| 99.1 | | Press Release of Aquinox Pharmaceuticals, Inc. dated January 11, 2016 |
